the results indicate that sulphinpyrazone reduces fibrin formation within artificial kidneys and , since the reduction in deposition of fibrin alone is insufficient to explain the higher plasma fibrinogen levels during treatment with sulphinpyrazone , suggests that this therapy reduces fibrinogen consumption within the patient during hemodialysis .
C0015982
fibrin
C0032105
plasma